---
figid: PMC6775706__jcav10p5504g002
figlink: /pmc/articles/PMC6775706/figure/F2/
number: Figure 2
caption: Signaling pathways associated with tumorigenesis and combined treatments
  that alleviate drug resistance. Pharmaceutical CDK4/6 inhibitors palbociclib, ribociclib,
  and abemaciclib directly inhibit CDK4/6 activity. Moreover, the upstream mitogenic
  forces, including the canonical RAS-RAF-MEK-ERK pathway, heightened activity of
  the HER2-PI3K-AKT-mTOR axis, increase the cyclin D1 levels, activating CDK4/6 and
  promoting cellular progression to the S phase. Because of this foundation, PI3K,
  mTOR and MEK inhibitors induce synergistic anti-proliferative and pro-apoptotic
  effects, which lead to more durable cell cycle arrest and a delay to the onset of
  resistance. The Aromatase Inhibitors (AI), which inhibit the transformation of androgen
  into estradiol, thereby suppress breast cancer cell growth. Selective estrogen receptor
  modulator (SERM) and selective estrogen receptor downregulator (SERD) can affect
  estrogen receptors to produce the same inhibitory effect on tumor cells. ALT can
  keep p27 in a non-phosphorylated state, which is a stable form, and reduce both
  CDK2 and CDK4 activity. BMP4 and Fangchinoline can upregulate p21. Fangchinoline
  not only increases the level of CKIs (p21 and p27), but also inhibits cyclin D1/D3/E
  and CDK2/4/6. The ALT, BMP4 and Fangchinoline are still under preclinical study.
  In addition, clinical studies on the combination of CDK4/6 inhibitors with anti-HER2
  therapy and immunotherapy are under way.
pmcid: PMC6775706
papertitle: 'Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status,
  Resistance, and Combination Strategies.'
reftext: Ying Niu, et al. J Cancer. 2019;10(22):5504-5517.
pmc_ranked_result_index: '23740'
pathway_score: 0.9395784
filename: jcav10p5504g002.jpg
figtitle: Signaling pathways associated with tumorigenesis and combined treatments
  that alleviate drug resistance
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6775706__jcav10p5504g002.html
  '@type': Dataset
  description: Signaling pathways associated with tumorigenesis and combined treatments
    that alleviate drug resistance. Pharmaceutical CDK4/6 inhibitors palbociclib,
    ribociclib, and abemaciclib directly inhibit CDK4/6 activity. Moreover, the upstream
    mitogenic forces, including the canonical RAS-RAF-MEK-ERK pathway, heightened
    activity of the HER2-PI3K-AKT-mTOR axis, increase the cyclin D1 levels, activating
    CDK4/6 and promoting cellular progression to the S phase. Because of this foundation,
    PI3K, mTOR and MEK inhibitors induce synergistic anti-proliferative and pro-apoptotic
    effects, which lead to more durable cell cycle arrest and a delay to the onset
    of resistance. The Aromatase Inhibitors (AI), which inhibit the transformation
    of androgen into estradiol, thereby suppress breast cancer cell growth. Selective
    estrogen receptor modulator (SERM) and selective estrogen receptor downregulator
    (SERD) can affect estrogen receptors to produce the same inhibitory effect on
    tumor cells. ALT can keep p27 in a non-phosphorylated state, which is a stable
    form, and reduce both CDK2 and CDK4 activity. BMP4 and Fangchinoline can upregulate
    p21. Fangchinoline not only increases the level of CKIs (p21 and p27), but also
    inhibits cyclin D1/D3/E and CDK2/4/6. The ALT, BMP4 and Fangchinoline are still
    under preclinical study. In addition, clinical studies on the combination of CDK4/6
    inhibitors with anti-HER2 therapy and immunotherapy are under way.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - CYP19A1
  - AKT3
  - PIK3CD
  - BMP4
  - AKT2
  - RAF1
  - BRAF
  - PIK3CG
  - ARAF
  - NRAS
  - CCND1
  - HRAS
  - KRAS
  - PIK3R4
  - PIK3CA
  - ERBB2
  - MAPK1
  - MAPK3
  - IGF1R
  - IRS1
  - CDK2
  - CDK6
  - CDK4
  - PIK3R3
  - PIK3CB
  - PIK3R6
  - PIK3R5
  - CCNE2
  - EGFR
  - MAP2K1
  - MAP2K2
  - MTOR
  - CCNE1
  - Androgen
  - Al
  - lapatinib
  - neratinib
  - letrozole
  - anastrozole
  - Estradiol
  - exemestane
  - everolimus
  - tamoxifen
  - toremifene
  - fulvestrant
  - Fangchinoline
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Aromatase
  symbol: aromatase
  source: hgnc_alias_symbol
  hgnc_symbol: CYP19A1
  entrez: '1588'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: BMP4
  symbol: BMP4
  source: hgnc_symbol
  hgnc_symbol: BMP4
  entrez: '652'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: CyclinD1
  symbol: Cyclin-D1
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: EGFR/HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: IGFR
  symbol: IGFR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: IRS-1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: CDK2
  symbol: CDK2
  source: hgnc_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE2
  entrez: '9134'
- word: EGFR/HER2
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: CyclinE
  symbol: Cyclin_E
  source: bioentities_symbol
  hgnc_symbol: CCNE1
  entrez: '898'
chemicals:
- word: Androgen
  source: MESH
  identifier: D000728
- word: Al
  source: MESH
  identifier: D000535
- word: lapatinib
  source: MESH
  identifier: C490728
- word: neratinib
  source: MESH
  identifier: C487932
- word: letrozole
  source: MESH
  identifier: C067431
- word: anastrozole
  source: MESH
  identifier: C090450
- word: Estradiol
  source: MESH
  identifier: D004958
- word: exemestane
  source: MESH
  identifier: C056516
- word: everolimus
  source: MESH
  identifier: C107135
- word: tamoxifen
  source: MESH
  identifier: D013629
- word: toremifene
  source: MESH
  identifier: D017312
- word: fulvestrant
  source: MESH
  identifier: C070081
- word: Fangchinoline
  source: MESH
  identifier: C060802
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
